Novel approaches are needed to develop tomorrow's antibacterial therapies

Brad Spellberg, John Bartlett, Rich Wunderink, David N. Gilbert

Research output: Contribution to journalArticle

Abstract

Society faces a crisis of rising antibiotic resistance even as the pipeline of new antibiotics has been drying up. Antibiotics are a public trust; every individual's use of antibiotics affects their efficacy for everyone else. As such, responses to the antibiotic crisis must take a societal perspective. The market failure of antibiotics is due to a combination of scientific challenges to discovering and developing new antibiotics, unfavorable economics, and a hostile regulatory environment. Scientific solutions include changing the way we screen for new antibiotics. More transformationally, developing new treatments that seek to disarm pathogens without killing them, or that modulate the host inflammatory response to infection, will reduce selective pressure and hence minimize resistance emergence. Economic transformation will require new business models to support antibiotic development. Finally, regulatory reform is needed so that clinical development programs are feasible, rigorous, and clinically relevant. Pulmonary and critical care specialists can have tremendous impact on the continued availability of effective antibiotics. Encouraging use of molecular diagnostic tests to allow pathogen-targeted, narrow-spectrum antibiotic therapy, using short rather than unnecessarily long course therapy, reducing inappropriate antibiotic use for probable viral infections, and reducing infection rates will help preserve the antibiotics we have for future generations.

Original languageEnglish (US)
Pages (from-to)135-140
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume191
Issue number2
DOIs
StatePublished - Jan 15 2015

Fingerprint

Anti-Bacterial Agents
Therapeutics
Economics
Molecular Pathology
Social Responsibility
Virus Diseases
Critical Care
Microbial Drug Resistance
Infection
Routine Diagnostic Tests
Lung

Keywords

  • Antibiotic resistance
  • Antibiotics
  • Drug
  • Market failure
  • Regulations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Medicine(all)

Cite this

Novel approaches are needed to develop tomorrow's antibacterial therapies. / Spellberg, Brad; Bartlett, John; Wunderink, Rich; Gilbert, David N.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 191, No. 2, 15.01.2015, p. 135-140.

Research output: Contribution to journalArticle

Spellberg, Brad ; Bartlett, John ; Wunderink, Rich ; Gilbert, David N. / Novel approaches are needed to develop tomorrow's antibacterial therapies. In: American Journal of Respiratory and Critical Care Medicine. 2015 ; Vol. 191, No. 2. pp. 135-140.
@article{a0d88636094645ababe933315abd5f94,
title = "Novel approaches are needed to develop tomorrow's antibacterial therapies",
abstract = "Society faces a crisis of rising antibiotic resistance even as the pipeline of new antibiotics has been drying up. Antibiotics are a public trust; every individual's use of antibiotics affects their efficacy for everyone else. As such, responses to the antibiotic crisis must take a societal perspective. The market failure of antibiotics is due to a combination of scientific challenges to discovering and developing new antibiotics, unfavorable economics, and a hostile regulatory environment. Scientific solutions include changing the way we screen for new antibiotics. More transformationally, developing new treatments that seek to disarm pathogens without killing them, or that modulate the host inflammatory response to infection, will reduce selective pressure and hence minimize resistance emergence. Economic transformation will require new business models to support antibiotic development. Finally, regulatory reform is needed so that clinical development programs are feasible, rigorous, and clinically relevant. Pulmonary and critical care specialists can have tremendous impact on the continued availability of effective antibiotics. Encouraging use of molecular diagnostic tests to allow pathogen-targeted, narrow-spectrum antibiotic therapy, using short rather than unnecessarily long course therapy, reducing inappropriate antibiotic use for probable viral infections, and reducing infection rates will help preserve the antibiotics we have for future generations.",
keywords = "Antibiotic resistance, Antibiotics, Drug, Market failure, Regulations",
author = "Brad Spellberg and John Bartlett and Rich Wunderink and Gilbert, {David N.}",
year = "2015",
month = "1",
day = "15",
doi = "10.1164/rccm.201410-1894OE",
language = "English (US)",
volume = "191",
pages = "135--140",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - Novel approaches are needed to develop tomorrow's antibacterial therapies

AU - Spellberg, Brad

AU - Bartlett, John

AU - Wunderink, Rich

AU - Gilbert, David N.

PY - 2015/1/15

Y1 - 2015/1/15

N2 - Society faces a crisis of rising antibiotic resistance even as the pipeline of new antibiotics has been drying up. Antibiotics are a public trust; every individual's use of antibiotics affects their efficacy for everyone else. As such, responses to the antibiotic crisis must take a societal perspective. The market failure of antibiotics is due to a combination of scientific challenges to discovering and developing new antibiotics, unfavorable economics, and a hostile regulatory environment. Scientific solutions include changing the way we screen for new antibiotics. More transformationally, developing new treatments that seek to disarm pathogens without killing them, or that modulate the host inflammatory response to infection, will reduce selective pressure and hence minimize resistance emergence. Economic transformation will require new business models to support antibiotic development. Finally, regulatory reform is needed so that clinical development programs are feasible, rigorous, and clinically relevant. Pulmonary and critical care specialists can have tremendous impact on the continued availability of effective antibiotics. Encouraging use of molecular diagnostic tests to allow pathogen-targeted, narrow-spectrum antibiotic therapy, using short rather than unnecessarily long course therapy, reducing inappropriate antibiotic use for probable viral infections, and reducing infection rates will help preserve the antibiotics we have for future generations.

AB - Society faces a crisis of rising antibiotic resistance even as the pipeline of new antibiotics has been drying up. Antibiotics are a public trust; every individual's use of antibiotics affects their efficacy for everyone else. As such, responses to the antibiotic crisis must take a societal perspective. The market failure of antibiotics is due to a combination of scientific challenges to discovering and developing new antibiotics, unfavorable economics, and a hostile regulatory environment. Scientific solutions include changing the way we screen for new antibiotics. More transformationally, developing new treatments that seek to disarm pathogens without killing them, or that modulate the host inflammatory response to infection, will reduce selective pressure and hence minimize resistance emergence. Economic transformation will require new business models to support antibiotic development. Finally, regulatory reform is needed so that clinical development programs are feasible, rigorous, and clinically relevant. Pulmonary and critical care specialists can have tremendous impact on the continued availability of effective antibiotics. Encouraging use of molecular diagnostic tests to allow pathogen-targeted, narrow-spectrum antibiotic therapy, using short rather than unnecessarily long course therapy, reducing inappropriate antibiotic use for probable viral infections, and reducing infection rates will help preserve the antibiotics we have for future generations.

KW - Antibiotic resistance

KW - Antibiotics

KW - Drug

KW - Market failure

KW - Regulations

UR - http://www.scopus.com/inward/record.url?scp=84921416935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921416935&partnerID=8YFLogxK

U2 - 10.1164/rccm.201410-1894OE

DO - 10.1164/rccm.201410-1894OE

M3 - Article

C2 - 25590154

AN - SCOPUS:84921416935

VL - 191

SP - 135

EP - 140

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -